Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Protagenic TherapeuticsPTIX -2.41%26 Cash-to-Debt is 0.55 as of Dec. 2025, which is 100% below its 10-year median of 5,025.69. GuruFocus rates PTIX with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,395 Biotechnology companies, Protagenic Therapeutics ranks worse than 83.73% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Protagenic Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2025 was 0.55.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Protagenic Therapeuticscouldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Protagenic Therapeutics's Cash-to-Debt or its related term are showing as below:
PTIX'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13 Med: 5025.69 Max: No Debt
Current: 0.55
During the past 13 years, Protagenic Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.13. And the median was 5025.69.
PTIX's Cash-to-Debt is ranked worse than 83.73% of 1395
companies
in the Biotechnology industry
Industry Median: 7.17
vs PTIX: 0.55
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Protagenic Therapeutics Cash-to-Debt Related Terms
Protagenic Therapeutics Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Protagenic Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Protagenic Therapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Protagenic Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Protagenic Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protagenic Therapeutics (PTIX) has a Cash-to-Debt of 0.55 as of Dec. 2025. This is 100% below median its historical median of 5,025.69. Over the past decade, Protagenic Therapeutics' Cash-to-Debt has ranged from 0.13 to 10,000.00. According to the industry distribution chart, Protagenic Therapeutics ranks #1168 out of 1395 companies in the Biotechnology industry, placing it in the top 83.7%.
Is Protagenic Therapeutics' Cash-to-Debt too high?
Protagenic Therapeutics' current Cash-to-Debt of 0.55 is 100% below median its 10-year median of 5,025.69. Over the past 10 years, this metric has ranged from a low of 0.13 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 7.17. Protagenic Therapeutics' value of 0.55 is 92.3% below this industry median. Based on the distribution chart, Protagenic Therapeutics ranks #1168 out of 1395 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Protagenic Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Protagenic Therapeutics' Cash-to-Debt compare to SCNI and DCOY?
According to the Biotechnology industry distribution chart, Protagenic Therapeutics ranks #1168 out of 1395 companies for Cash-to-Debt. This places Protagenic Therapeutics in the lower half of its industry. The industry median Cash-to-Debt is 7.17. Protagenic Therapeutics' value of 0.55 is 92.3% below this benchmark. Historically, Protagenic Therapeutics' own Cash-to-Debt has ranged from 0.13 to 10,000.00 over the past decade. While the company's 10-year median is 5,025.69 vs. the industry median of 7.17, Protagenic Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.17, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Protagenic Therapeutics's current Cash-to-Debt of 0.55 is 92.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Protagenic Therapeutics's current Cash-to-Debt is 0.55, which is 100% below median its own 10-year median of 5,025.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protagenic Therapeutics stock overvalued right now?
Protagenic Therapeutics (PTIX) has a current Cash-to-Debt of 0.55. The current Cash-to-Debt is 0.55, which is 100% below median its 10-year median of 5,025.69 and 92.3% below the Biotechnology industry median of 7.17. Protagenic Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Protagenic Therapeutics (PTIX), the current Cash-to-Debt is 0.55 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
26GF Score
Get the complete analysis for PTIX
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTIX has been successfully added to your 
